Robert W Buckingham¹* and Brittany Adams²

¹University of Michigan, Flint, Michigan, United States

*Corresponding Author: Robert W Buckingham, Department of Public Health, University of Michigan, Flint, Michigan, United States.

Received: August 08, 2022; Published: August 23, 2022

Abstract

COVID-19 is an ever-evolving virus. Quickly appearing and disappearing variants make it difficult to keep up with necessary changes in response. In 2021, WHO created a new naming system to help distinguish different variants. It has been crucial in identifying the many subvariants of Omicron, including the now majority BA.5. Vaccine manufacturers have been working to create boosters that are more effective against variants that have proven evasive of immunity provided by current vaccines. Scientists are divided about the best path forward for these new vaccines, especially concerning future unknown variants. It is impossible to know how long Omicron will be around or if, even in a few weeks, we will have a new variant taking its place.

Keywords: COVID-19; Omicron; Variants; Vaccines; WHO; FDA

References

1. European Centre for Disease Prevention and Control (ECDC). “Epidemiological Update: SARS-CoV-2 Omicron sub-lineages BA.4 and BA.5”. (2022).
2. Pango Network. “What are Pango lineages?”. Pango Lineage Nomenclature, (2021).
3. World Health Organization (WHO). “Who announces simple easy-to-say labels for SARS-CoV-2 Variants of Interest and Concern” (2021).
4. World Health Organization (WHO). “Tracking SARS-CoV-2 Variants” (2022).
5. Lambrou AS., et al. “Genomic Surveillance for SARS-CoV-2 Variants: Predominance of the Delta (B.1.617.2) and Omicron (B.1.1.529) Variants — United States, June 2021–January 2022”. MMWR (2022).
6. Centers for Disease Control and Prevention (CDC). “Variant Proportions. COVID Data Tracker” (2022).
7. Callaway Ewen. “What the latest Omicron subvariants mean for the pandemic”. Nature 606 (2022).
8. Centers for Disease Control and Prevention (CDC). “Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June 2022”. MMWR (2022).
9. Marks Peter. “Coronavirus (COVID-19) Update: FDA Recommends Inclusion of Omicron BA.4/5 Component for COVID-19 Vaccine Booster Doses”. U.S. Food and Drug Administration, (2022).
10. Rubin Rita. “COVID-19 Boosters This Fall to Include Omicron Antigen, but Questions Remain About Its Value”. Journal of the American Medical Association (2022).
11. Callaway Ewen. “Fast-evolving COVID variants complicate vaccine updates”. Nature 607 (2022).
12. Aldridge Randy. “Is BA.2.75 the Next Big Threat?”. North Carolina Medical Society (2022).

Citation

Citation: Robert W Buckingham and Brittany Adams. “Evolution of COVID-19 Practices and Overview of Current Variants of Concern". Acta Scientific Microbiology 5.9 (2022): 140-144.

Copyright

Copyright: © 2022 Robert W Buckingham and Brittany Adams. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.